Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutics for neurological disorders

A technology for therapeutic agents and motor neurons, applied in the field of therapeutic agents, can solve the problems of narrowing the high polarity of the therapeutic window

Inactive Publication Date: 2011-11-16
UNIV OF SHEFFIELD
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This therapeutic effect was found despite the fact that EGCG itself is a pro-oxidant, thereby narrowing its therapeutic window and its high polarity making it impossible to cross the blood-brain barrier in significant concentrations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutics for neurological disorders
  • Therapeutics for neurological disorders
  • Therapeutics for neurological disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0098] The 4×ARE-TK-GFP and TK-GFP reporter cell lines were tested for their response to a series of concentrations of the known ARE inducer tert-butyl hydroquinone (tBHQ) and the flavonoid EGCG. The compound was applied in triplicate to confluent cells in a serum-free culture in a 96-well plate for 24 hours. Detect the induction of GFP in a fluorescence plate reader. Both compounds induce GFP expression in a narrow window, with the peak value of EGCG at 100 μM and the peak value of tBHQ at 10 μM ( figure 2 a). At concentrations above this peak expression, both compounds showed signs of toxicity by direct observation (cell loss) or increased ethidium bromide dimer fluorescence. No increase in fluorescence was observed in the control TK-GFP cell line (not shown).

Embodiment 2

[0100] To screen the spectrum collection of 2000 molecules, the reporter assay was scaled down to a 384-well-plate format. In order to evaluate the suitability of the assay for library screening, Z'score calculation was performed by treating candidate wells with medium (0.1% DMSO) and 10 μM ebselen as a positive control (see calculation in method). We have shown that ebselen gives a strong concentration response curve in this determination. The calculated Z’ score is 0.51( figure 2 b), this is acceptable by the library screening. In addition, the signal-to-noise ratio (S / N) and the signal to background (S / B) ratio are acceptable, at 12.8 and 2.9, respectively. The library was then screened at a single concentration of 10 μM for each compound. The drug library dilution and plating were performed by the Q-BOT liquid handling system, and the reaction of the 4×ARE-TK-GFP and TK-GFP reporter cell lines to the compound was tested. image 3 An example set of ARE-TK-GFP cell line da...

Embodiment 3

[0102] To study the effect of Nrf2-ARE-induced sampling compounds on oxidative stress induced by serum deprivation in motor neurons and astrocytes. Since the activation of this pathway can vary with cell type, we continue to screen how well these sampled compounds protect motor nerve cell lines (NSC34 cells) and rat (C6) and human (1321N1) astrocytes It is free from oxidative stress induced by serum deprivation. The cell line was pretreated with a series of concentrations of sampling compounds for 24 hours to activate the NRF2-ARE pathway. The compound was then discarded, and the cells were subjected to serum deprivation for 6 hours to induce oxidative stress. Dichlorofluorescein (DCF) fluorescence was used to detect the degree of oxidative stress, and the degree of protection was shown in Table 3, as the percentage of DCF fluorescence of each of the three cell lines was reduced. If it is possible to fit the curve, you can also quote the semi-maximum effect (IC 50 ) The requi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to therapeutic compounds that are Nrf2-ARE pathway activators suitable for the treatment of diseases known to be mediated by oxidative stress such as motor neurone disease. The invention also includes compounds identified by the methods of the invention for treatment of neurodegenerative diseases.

Description

Invention field [0001] The present invention relates to therapeutic agents for the treatment of neurological disorders known to be mediated by oxidative stress, especially for the treatment of motor neuron diseases and amyotrophic lateral sclerosis. The invention specifically includes products for treating neurological disorders. Background of the invention [0002] Oxidative stress refers to the cytopathological consequences of a mismatch between the production of free radicals and the ability of cells to defend them. Increasing data from experimental models and human brain studies suggest that oxidative stress may play an important role in neurodegenerative diseases. Oxidative stress is associated with normal aging and various neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis, and can cause necrosis, death Common mechanisms of various forms of cell death, including death and excitotoxicity. [0003] Motor neuron dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61K31/473A61P25/28
CPCA61K31/366A61K31/473A61P17/00A61P25/00A61P25/02A61P25/14A61P25/16A61P25/28A61P27/02A61P43/00
Inventor 帕梅拉·邵理查德·米德艾德里安·希金伯特姆思安·巴伯
Owner UNIV OF SHEFFIELD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com